FIELD: biotechnology.
SUBSTANCE: The invention relates to the field of biotechnology. Created are a genetic construct for the expression of recombinant SARS-CoV-2 virus protein RBD, a strain of Chinese hamster ovary cells CHO-S-RBD that produces a recombinant protein - a receptor-binding domain (RBD) of SARS-CoV-2 virus, which can be used for diagnostic purposes. Described is a method for producing a strain of Chinese hamster ovary cells CHO-S-RBD being a producer of recombinant SARS-CoV-2 virus protein RBD, containing a genetic construct comprising SEQ ID NO: 1; introducing the specified genetic constructs into cells by lipofection; selecting cells on Hygromycin B antibiotic. Created is a strain of Chinese hamster ovary cells CHO-S-RBD, a producer of recombinant SARS-CoV-2 virus protein RBD. Developed is a method for producing recombinant SARS-CoV-2 virus protein RBD, comprising: culturing a strain of Chinese hamster ovary cells CHO-S-RBD; purifying chromatographically the recombinant SARS-CoV-2 virus protein RBD from culture medium of the Chinese hamster ovary strain CHO-S-RBD; confirming the production of recombinant SARS-CoV-2 protein RBD. Created is a recombinant SARS-CoV-2 virus protein RBD to detect antibodies to SARS-CoV-2. Created is a test system for enzyme immunoassay of human serum or plasma. Developed is a method for analyzing serum or plasma of COVID-19 convalescents to sample the most promising ones for treating patients infected with SARS-CoV-2. Developed is a method for analyzing human serum or plasma to determine the titer of antibodies to SARS-CoV-2 virus. The invention reduces time and simplifies the analysis of serum or plasma of COVID-19 convalescents to sample the most promising ones for treating SARS-CoV-2 infected patients. The invention also provides for high and stable expression of recombinant SARS-CoV-2 virus protein RBD.
EFFECT: invention provides a rapid and efficient test system for determining the most promising serum or plasma samples of COVID-19 convalescents for treating patients infected with SARS-CoV-2.
10 cl, 4 dwg, 6 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS | 2020 |
|
RU2730897C1 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
| THE STRAIN OF HYBRID CULTURED HOMO SAPIENS/Mus MUSCULUS CELLS Hu-C6D7-RBD IS A PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE RBD DOMAIN S OF THE SARS-CoV-2 VIRUS PROTEIN | 2022 |
|
RU2788359C1 |
| TEST SYSTEM AND METHOD FOR DIFFERENTIAL DETECTION OF ANTIBODIES TO SARS-COV-2 | 2021 |
|
RU2754340C1 |
| RECOMBINANT SARS-CoV-2 S PROTEIN RBD-BINDING PROTEIN | 2022 |
|
RU2778942C1 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| STRAIN OF HCOV-19/RUSSIA/OMSK-202118-1707/2020 OF SARS-COV-2 CORONAVIRUS, IMMUNOSORBENT CONTAINING PURIFIED WHOLE VIRION ANTIGEN OBTAINED ON BASIS OF SPECIFIED STRAIN AND ISA TEST SYSTEM FOR DETECTING ANTIBODIES OF CLASSES M, G AND A TO SARS CORONAVIRUS-COV-2 USING SPECIFIED IMMUNOSORBENT | 2021 |
|
RU2752862C1 |
| INTEGRATIVE PLASMID VECTOR PVEAL2-S-RBD, PROVIDING THE EXPRESSION AND SECRETION OF THE RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF THE SARS-COV-2 CORONAVIRUS IN MAMMALIAN CELLS, THE RECOMBINANT CHO-K1-RBD CELL LINE STRAIN AND THE RECOMBINANT SARS-COV-2 RBD PROTEIN PRODUCED BY THE SPECIFIED STRAIN OF THE CELL LINE CHO-K1-RBD | 2021 |
|
RU2752858C1 |
